Together, it is clear that anti-IGF-IR agents may paradoxically stimulate tumor microenvironment remodeling to boost IGF signaling through alternative pathways, leading to cancer resistance to anti-IGF-IR agents. The gene discussed is IGF1; the disease is neoplasm.